Medicus Pharma (NASDAQ:MDCX) has reported second quarter financial results and regulatory and clinic

Medicus Pharma (NASDAQ:MDCX) reported quarterly losses of $(0.21) per share which missed the analyst

Company Highlights Significant Regulatory, Clinical and Strategic Progress Across SkinJect® and Teve

SK Hynix Inc (NASDAQ:SKHY) has received an ‘Outperform’ rating from Wedbush on Tuesday as the firm i

Medicus Pharma (NASDAQ:MDCX) announced it has put its chief medical officer in charge of UK subsidia

Dr. Mehmud's appointment further aligns the scientific, clinical, regulatory and operational leaders

Medicus Pharma (NASDAQ:MDCX) earlier this week announced that the US Food and Drug Administration (F

Medicus Pharma (NASDAQ:MDCX) earlier this week announced that the US Food and Drug Administration (F

Gainers Universe Pharmaceuticals (NASDAQ:UPC) stock increased by 91.1% to $6.04 during Friday's

Medicus Pharma (NASDAQ:MDCX) announced that the United Arab Emirates Department of Health – Abu Dhab

Roblox Corp (NYSE:RBLX) shares fell nearly 30% to around $34 following the company’s second quarter

Randomized Phase 2a PRECISION-E2 study designed to evaluate a predefined panel of genes to advance p

Medicus Pharma obtained UAE approval for its PRECISION-E2 Phase 2a clinical trial testing Teverelix

Reddit Inc (NYSE:RDDT) shares fell about 21% on Friday morning after management warned of volatility

Medicus Pharma (NASDAQ:MDCX) announced that the United Arab Emirates Department of Health – Abu Dhab

Honeywell International Inc (NYSE:HON, XETRA:ALD) was upgraded to ‘Neutral’ from ‘Underperform’ by B

Medicus Pharma (NASDAQ:MDCX) said the US Food and Drug Administration (FDA) has issued a "Study May

Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life scien

SKNJCT-005 registrational clinical study protocol strengthened through planned implementation of FDA

Nvidia Corp (NASDAQ:NVDA, XETRA:NVD) is in talks to provide a roughly $250 billion financial guarant

Gainers China SXT Pharmaceuticals (NASDAQ:SXTC) shares moved upwards by 41.1% to $0.09 during Frida

Medicus Pharma (NASDAQ:MDCX) earlier this week provided an update on its redesigned clinical study f

Medicus Pharma (NASDAQ:MDCX) earlier this week provided an update on its redesigned clinical study f

Medicus Pharma (NASDAQ:MDCX) said it has received US FDA feedback and central Institutional Review B

Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life scien

Regulatory and ethical-review milestones advance a capital-efficient Phase 2 study expected to enrol

Gainers Shuttle Pharmaceuticals (NASDAQ:SHPH) shares rose 56.1% to $4.62 during Monday's after-

Gainers Curis (NASDAQ:CRIS) stock rose 9.0% to $0.46 during Wednesday's after-market session. T

Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a biotech/life scie

Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life scien

Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life scien

Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a biotech/life scie

Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life scien

Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life scien

Medicus Pharma (NASDAQ:MDCX) reported quarterly losses of $(0.31) per share which missed the analyst

Medicus Pharma reports dose-response in Phase 2 BCC study, with 200µg cohort showing the strongest e

200μg Cohort Achieves 55% Complete Response at Day 57 Emerging asRegistrational Grade Lead RegimenTh

Organon & Co (OGN) jumped 14.8% in pre-market trading as Sun Pharma agreed to acquire the compan

Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life scien

J B Hunt Transport Services Inc (JBHT) stock rose in pre-market trading after beating earnings estim

Medicus Pharma to present Phase 1 Teverelix data showing dose-dependent estradiol suppression and lo

Medicus Pharma submits Phase 2 design for Teverelix, targeting faster data readouts and lower costs

Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life scien

Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life scien

Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life scien

Medicus Pharma (NASDAQ:MDCX) reported quarterly losses of $(0.83) per share which missed the analyst

Phase 2 Study Demonstrated 73% clinical Clearance in the 200-µg Arm suggests that ~3 out of 4 treate